Therapeutic Efficacy of Sorafenib and Plant-derived Phytochemicals in Human Colorectal Cancer Cells

Overview

Journal BMC Complement Med Ther

Publisher Biomed Central

Specialty Rehabilitation Medicine

Date 2023 Jun 26

PMID 37365571

Authors

Abdulmajeed Bahman

Mohamed-Salah Abaza

Sarah Khoushaish

Rajaa J Al-Attiyah

Affiliations

Soon will be listed here.

Abstract

Background: The present study aimed to investigate the sequence-dependent anticancer effects of combined treatment with sorafenib (Sora), a Food and Drug Administration-approved multikinase inhibitor drug, and plant-derived phytochemicals (PPCs) on human colorectal cancer (CRC) cell growth, and proteins associated with the control of cell cycle and apoptosis.

Methods: The cytotoxic effects of 14 PPCs on CRL1554 fibroblast cells were determined using an MTT assay. Moreover, the cytotoxicity of Sora, PPCs, and a combination of both on CRC cells were also investigated. Cell cycle analysis was performed using flow cytometry, and cell apoptosis was investigated using DNA fragmentation, Annexin V/propidium iodide double staining, and mitochondrial membrane potential analyses. The cell cycle- and apoptosis-associated protein expression levels were analysed using western blotting.

Results: Based on their low levels of cytotoxicity in CRL1554 cells at ≤ 20%, curcumin, quercetin, kaempferol, and resveratrol were selected for use in subsequent experiments. The combined treatment of sora and PPCs caused levels of CRC cytotoxicity in a dose-, cell type-, and schedule-dependent manner. Moreover, the combined treatment of CRC cells arrested cell growth at the S and G2/M phases, induced apoptotic cell death, caused extensive mitochondrial membrane damage, and altered the expression of the cell cycle and apoptotic proteins.

Conclusions: Results of the present study highlighted a difference in the level of sora efficacy in CRC cells when combined with PPCs. Further in vivo and clinical studies using the combined treatment of sora and PPCs are required to determine their potential as a novel therapeutic strategy for CRCs.

References

Tomizawa M, Shinozaki F, Sugiyama T, Yamamoto S, Sueishi M, Yoshida T . Sorafenib suppresses the cell cycle and induces the apoptosis of hepatocellular carcinoma cell lines in serum-free media. Exp Ther Med. 2012; 1(5):863-866. PMC: 3445901. DOI: 10.3892/etm.2010.131. View

Bahman A, Abaza M, Khoushiash S, Al-Attiyah R . Sequence‑dependent effect of sorafenib in combination with natural phenolic compounds on hepatic cancer cells and the possible mechanism of action. Int J Mol Med. 2018; 42(3):1695-1715. PMC: 6089756. DOI: 10.3892/ijmm.2018.3725. View

Weng C, Yen G . Chemopreventive effects of dietary phytochemicals against cancer invasion and metastasis: phenolic acids, monophenol, polyphenol, and their derivatives. Cancer Treat Rev. 2011; 38(1):76-87. DOI: 10.1016/j.ctrv.2011.03.001. View

Kastan M, Bartek J . Cell-cycle checkpoints and cancer. Nature. 2004; 432(7015):316-23. DOI: 10.1038/nature03097. View

Fisher D . Apoptosis in cancer therapy: crossing the threshold. Cell. 1994; 78(4):539-42. DOI: 10.1016/0092-8674(94)90518-5. View

Vermeulen K, Bockstaele D, Berneman Z . The cell cycle: a review of regulation, deregulation and therapeutic targets in cancer. Cell Prolif. 2003; 36(3):131-49. PMC: 6496723. DOI: 10.1046/j.1365-2184.2003.00266.x. View

Heim M, Sharifi M, Hilger R, Scheulen M, Seeber S, Strumberg D . Antitumor effect and potentiation or reduction in cytotoxic drug activity in human colon carcinoma cells by the Raf kinase inhibitor (RKI) BAY 43-9006. Int J Clin Pharmacol Ther. 2003; 41(12):616-7. DOI: 10.5414/cpp41616. View

Kuo Y, Lin W, Chiang I, Chang Y, Chen C, Su S . Sorafenib sensitizes human colorectal carcinoma to radiation via suppression of NF-κB expression in vitro and in vivo. Biomed Pharmacother. 2012; 66(1):12-20. DOI: 10.1016/j.biopha.2011.09.011. View

Kong J, Kong F, Gao J, Zhang Q, Dong S, Gu F . YC-1 enhances the anti-tumor activity of sorafenib through inhibition of signal transducer and activator of transcription 3 (STAT3) in hepatocellular carcinoma. Mol Cancer. 2014; 13:7. PMC: 3895679. DOI: 10.1186/1476-4598-13-7. View

10.

Chiruvella K, Raghavan S . A natural compound, methyl angolensate, induces mitochondrial pathway of apoptosis in Daudi cells. Invest New Drugs. 2010; 29(4):583-92. DOI: 10.1007/s10637-010-9393-7. View

11.

Kasibhatla S, Tseng B . Why target apoptosis in cancer treatment?. Mol Cancer Ther. 2003; 2(6):573-80. View

12.

Heim M, Scharifi M, Zisowsky J, Jaehde U, Voliotis D, Seeber S . The Raf kinase inhibitor BAY 43-9006 reduces cellular uptake of platinum compounds and cytotoxicity in human colorectal carcinoma cell lines. Anticancer Drugs. 2005; 16(2):129-36. DOI: 10.1097/00001813-200502000-00003. View

13.

Chang Y, Hsu W, Chang C, Lan K, Ting G, Lee T . Combined therapeutic efficacy of Re-liposomes and sorafenib in an experimental colorectal cancer liver metastasis model by intrasplenic injection of C26- murine colon cancer cells. Mol Clin Oncol. 2014; 2(3):380-384. PMC: 3999117. DOI: 10.3892/mco.2014.246. View

14.

Nair B, Anto R, M S, Nath L . Kaempferol-Mediated Sensitization Enhances Chemotherapeutic Efficacy of Sorafenib Against Hepatocellular Carcinoma: An and Approach. Adv Pharm Bull. 2020; 10(3):472-476. PMC: 7335979. DOI: 10.34172/apb.2020.058. View

15.

Yan Y, Wang L, He J, Liu P, Lv X, Zhang Y . Synergy with interferon-lambda 3 and sorafenib suppresses hepatocellular carcinoma proliferation. Biomed Pharmacother. 2017; 88:395-402. DOI: 10.1016/j.biopha.2017.01.077. View

16.

Hosseini S, Chamani J, Sinichi M, Bonakdar A, Azad Z, Ahangari N . The effect of nanomicelle curcumin, sorafenib, and combination of the two on the cyclin D1 gene expression of the hepatocellular carcinoma cell line (HUH7). Iran J Basic Med Sci. 2020; 22(10):1198-1202. PMC: 6885396. DOI: 10.22038/ijbms.2019.35808.8530. View

17.

Li J, Cheung H, Zhang Z, Chan G, Fong W . Andrographolide induces cell cycle arrest at G2/M phase and cell death in HepG2 cells via alteration of reactive oxygen species. Eur J Pharmacol. 2007; 568(1-3):31-44. DOI: 10.1016/j.ejphar.2007.04.027. View

18.

Hanahan D, Weinberg R . Hallmarks of cancer: the next generation. Cell. 2011; 144(5):646-74. DOI: 10.1016/j.cell.2011.02.013. View

19.

Segal N, Saltz L . Evolving treatment of advanced colon cancer. Annu Rev Med. 2009; 60:207-19. DOI: 10.1146/annurev.med.60.041807.132435. View

20.

Khan N, Afaq F, Mukhtar H . Cancer chemoprevention through dietary antioxidants: progress and promise. Antioxid Redox Signal. 2007; 10(3):475-510. DOI: 10.1089/ars.2007.1740. View